Is BLTE or PRGO more profitable?

Belite Bio has a net margin of 0.00% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% Perrigo -41.85% 11.25% 4.08%

Does the media prefer BLTE or PRGO?

In the previous week, Belite Bio had 3 more articles in the media than Perrigo. MarketBeat recorded 5 mentions for Belite Bio and 2 mentions for Perrigo. Perrigo's average media sentiment score of 0.63 beat Belite Bio's score of 0.20 indicating that Perrigo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Perrigo 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, PRGO or LNTH?

Lantheus has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Perrigo $4.25B 0.46 -$1.43B -$12.51 N/A Lantheus $1.54B 4.23 $233.56M $4.14 24.12

Is PRGO or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Perrigo's net margin of -41.85%. Lantheus' return on equity of 28.10% beat Perrigo's return on equity. Company Net Margins Return on Equity Return on Assets Perrigo -41.85% 11.25% 4.08% Lantheus 17.69% 28.10% 14.35%

Does the media favor PRGO or LNTH?

In the previous week, Lantheus had 9 more articles in the media than Perrigo. MarketBeat recorded 11 mentions for Lantheus and 2 mentions for Perrigo. Perrigo's average media sentiment score of 0.63 beat Lantheus' score of 0.23 indicating that Perrigo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, PRGO or LQDA?

Liquidia has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Perrigo $4.25B 0.46 -$1.43B -$12.51 N/A Liquidia $158.32M 16.30 -$68.92M $1.37 21.05

Is PRGO or LQDA more profitable?

Liquidia has a net margin of 30.74% compared to Perrigo's net margin of -41.85%. Liquidia's return on equity of 149.65% beat Perrigo's return on equity. Company Net Margins Return on Equity Return on Assets Perrigo -41.85% 11.25% 4.08% Liquidia 30.74% 149.65% 36.30%

Does the media prefer PRGO or LQDA?

In the previous week, Liquidia had 27 more articles in the media than Perrigo. MarketBeat recorded 29 mentions for Liquidia and 2 mentions for Perrigo. Perrigo's average media sentiment score of 0.63 beat Liquidia's score of 0.28 indicating that Perrigo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 7 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to AMRX or PRGO?

In the previous week, Amneal Pharmaceuticals and Amneal Pharmaceuticals both had 2 articles in the media. Perrigo's average media sentiment score of 0.63 beat Amneal Pharmaceuticals' score of 0.51 indicating that Perrigo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Perrigo 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DFTX or PRGO?

In the previous week, Definium Therapeutics had 18 more articles in the media than Perrigo. MarketBeat recorded 20 mentions for Definium Therapeutics and 2 mentions for Perrigo. Perrigo's average media sentiment score of 0.63 beat Definium Therapeutics' score of 0.32 indicating that Perrigo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Perrigo 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Perrigo (PRGO) Competitors

$14.29 +0.27 (+1.93%)

As of 02:10 PM Eastern

Compare

PRGO vs. BLTE, LNTH, LQDA, AMRX, and DFTX

Should you buy Perrigo stock or one of its competitors? Perrigo's main competitors and comparable companies include Belite Bio (BLTE), Lantheus (LNTH), Liquidia (LQDA), Amneal Pharmaceuticals (AMRX), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Perrigo compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Perrigo (NYSE:PRGO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

Belite Bio currently has a consensus price target of $218.73, suggesting a potential upside of 33.54%. Perrigo has a consensus price target of $19.33, suggesting a potential upside of 35.72%. Given Perrigo's higher possible upside, analysts plainly believe Perrigo is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Belite Bio has a net margin of 0.00% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Perrigo	-41.85%	11.25%	4.08%

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 0.4% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Belite Bio has higher earnings, but lower revenue than Perrigo. Belite Bio is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Perrigo	$4.25B	0.46	-$1.43B	-$12.51	N/A

In the previous week, Belite Bio had 3 more articles in the media than Perrigo. MarketBeat recorded 5 mentions for Belite Bio and 2 mentions for Perrigo. Perrigo's average media sentiment score of 0.63 beat Belite Bio's score of 0.20 indicating that Perrigo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Perrigo	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Perrigo beats Belite Bio on 8 of the 15 factors compared between the two stocks.

How does Perrigo compare to Lantheus?

Perrigo (NYSE:PRGO) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Lantheus has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.46	-$1.43B	-$12.51	N/A
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.12

Perrigo has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Perrigo currently has a consensus target price of $19.33, indicating a potential upside of 35.72%. Lantheus has a consensus target price of $108.11, indicating a potential upside of 8.26%. Given Perrigo's higher probable upside, equities analysts plainly believe Perrigo is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Lantheus has a net margin of 17.69% compared to Perrigo's net margin of -41.85%. Lantheus' return on equity of 28.10% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-41.85%	11.25%	4.08%
Lantheus	17.69%	28.10%	14.35%

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 0.4% of Perrigo shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Lantheus had 9 more articles in the media than Perrigo. MarketBeat recorded 11 mentions for Lantheus and 2 mentions for Perrigo. Perrigo's average media sentiment score of 0.63 beat Lantheus' score of 0.23 indicating that Perrigo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lantheus beats Perrigo on 12 of the 16 factors compared between the two stocks.

How does Perrigo compare to Liquidia?

Perrigo (NYSE:PRGO) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Perrigo has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Liquidia has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perrigo	$4.25B	0.46	-$1.43B	-$12.51	N/A
Liquidia	$158.32M	16.30	-$68.92M	$1.37	21.05

In the previous week, Liquidia had 27 more articles in the media than Perrigo. MarketBeat recorded 29 mentions for Liquidia and 2 mentions for Perrigo. Perrigo's average media sentiment score of 0.63 beat Liquidia's score of 0.28 indicating that Perrigo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Perrigo	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	7 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

95.9% of Perrigo shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 0.4% of Perrigo shares are owned by insiders. Comparatively, 25.6% of Liquidia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Liquidia has a net margin of 30.74% compared to Perrigo's net margin of -41.85%. Liquidia's return on equity of 149.65% beat Perrigo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Perrigo	-41.85%	11.25%	4.08%
Liquidia	30.74%	149.65%	36.30%

Perrigo presently has a consensus price target of $19.33, suggesting a potential upside of 35.72%. Liquidia has a consensus price target of $85.83, suggesting a potential upside of 197.65%. Given Liquidia's stronger consensus rating and higher possible upside, analysts clearly believe Liquidia is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Liquidia	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.25

Summary

Liquidia beats Perrigo on 13 of the 17 factors compared between the two stocks.

How does Perrigo compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Perrigo (NYSE:PRGO) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Perrigo	-41.85%	11.25%	4.08%

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 0.4% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amneal Pharmaceuticals has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market.

In the previous week, Amneal Pharmaceuticals and Amneal Pharmaceuticals both had 2 articles in the media. Perrigo's average media sentiment score of 0.63 beat Amneal Pharmaceuticals' score of 0.51 indicating that Perrigo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals currently has a consensus price target of $21.00, indicating a potential upside of 4.87%. Perrigo has a consensus price target of $19.33, indicating a potential upside of 35.72%. Given Perrigo's higher probable upside, analysts clearly believe Perrigo is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Amneal Pharmaceuticals has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	2.12	$72.06M	$0.49	40.87
Perrigo	$4.25B	0.46	-$1.43B	-$12.51	N/A

Summary

Amneal Pharmaceuticals beats Perrigo on 10 of the 15 factors compared between the two stocks.

How does Perrigo compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Perrigo (NYSE:PRGO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Definium Therapeutics has higher earnings, but lower revenue than Perrigo. Definium Therapeutics is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Perrigo	$4.25B	0.46	-$1.43B	-$12.51	N/A

In the previous week, Definium Therapeutics had 18 more articles in the media than Perrigo. MarketBeat recorded 20 mentions for Definium Therapeutics and 2 mentions for Perrigo. Perrigo's average media sentiment score of 0.63 beat Definium Therapeutics' score of 0.32 indicating that Perrigo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Perrigo	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Definium Therapeutics currently has a consensus price target of $64.88, suggesting a potential upside of 74.21%. Perrigo has a consensus price target of $19.33, suggesting a potential upside of 35.72%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Definium Therapeutics is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	3.00
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by company insiders. Comparatively, 0.4% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Definium Therapeutics has a net margin of 0.00% compared to Perrigo's net margin of -41.85%. Perrigo's return on equity of 11.25% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Perrigo	-41.85%	11.25%	4.08%

Summary

Definium Therapeutics beats Perrigo on 10 of the 16 factors compared between the two stocks.

Get Perrigo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRGO vs. The Competition

Export

Metric	Perrigo	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.98B	$12.22B	$7.11B	$22.71B
Dividend Yield	7.86%	2.63%	2.53%	3.74%
P/E Ratio	-1.14	799.69	274.44	27.83
Price / Sales	0.47	751.71	608.01	20.26
Price / Cash	2.79	81.79	77.38	39.56
Price / Book	0.67	10.53	10.95	4.65
Net Income	-$1.43B	$2.84B	$3.50B	$1.08B
7 Day Performance	-7.36%	-1.74%	-2.16%	-0.99%
1 Month Performance	-1.35%	-6.02%	-6.41%	-4.96%
1 Year Performance	-35.53%	-3.74%	8.85%	5.83%

Perrigo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRGO Perrigo	3.6514 of 5 stars	$14.29 +1.9%	$19.33 +35.3%	-37.6%	$1.98B	$4.25B	N/A	8,100
BLTE Belite Bio	3.345 of 5 stars	$173.40 +1.4%	$218.73 +26.1%	+121.7%	$6.88B	N/A	N/A	41
LNTH Lantheus	3.2464 of 5 stars	$100.28 -0.3%	$108.11 +7.8%	+93.0%	$6.56B	$1.54B	24.22	1,193
LQDA Liquidia	3.9666 of 5 stars	$66.43 -0.7%	$98.08 +47.6%	+26.9%	$5.99B	$158.32M	48.49	216	Trending News Analyst Forecast
AMRX Amneal Pharmaceuticals	2.6229 of 5 stars	$20.16 +7.7%	$20.14 -0.1%	+93.4%	$5.98B	$3.02B	41.14	8,500	Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PRGO) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Perrigo (PRGO) Competitors